News Hub | News Direct

Professional Services

Architecture CRM/Customer Service Consulting Government & Policy Human Resources Intellectual Property/Trademark/Patent Law Legal
Article thumbnail News Release

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Corp

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024. Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, on Thursday, October 17, 2024, at 9:30am ET. The event will be streamed live on M-Vest and accessible to members by clicking here or via following link: https://m-vest.com/events/healthcare-10152024. The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting. About Silexion Therapeutics: Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com Contact Details Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com ARX | Capital Markets Advisors North American Equities Desk silexion@arxadvisory.com

October 09, 2024 04:30 PM Eastern Daylight Time

Article thumbnail News Release

MOU BETWEEN THE U.S. AND PERU PROVIDES A STEPPING STONE FOR MINING COMPANIES AT MINEXPO 2024

Promperu

With the new memorandum of understanding (MOU) signed between the United States of America (U.S.) and Peru, over 300 delegates -- the largest Peruvian business delegation ever – showed up in force at MINEXPO 2024, the premiere mining conference for the industry. Sponsored by the National Mining Association, it was held recently in Las Vegas. This underscores the importance of the relationship between the U.S. and Peru, a top producer of crucial minerals such as copper, lithium, silver and rare earth elements, essential for manufacturing a range of products, including cell phones, computers, and renewable energy technologies. As the U.S. transitions to green energy, these minerals are vital for producing batteries, electric vehicles, and other clean technologies, potentially saving the country billions in energy costs and enhancing energy independence. “Expanding the supply access to crucial minerals including copper and lithium, both of which are required for green energy technology, is essential,” emphasized Alvaro Silva-Santisteban, the ​ Executive ​ ​ Director ​ of PROMPERU in the U.S., which is the Investment, Trade and Tourism Commission of Peru. “As a result, Peru fortifies its world leadership as a natural location for mining companies seeking to expand production.” The MOU, which was finalized last August, opens the door to more mining opportunities for Foreign Direct Investment (FDI) and clears the way for the U.S. and Peru to partner on the extraction of a small portion of Peruvian green technologies. “Peru, with its vast reserves of copper, zinc, lithium, and other important minerals, is an invaluable partner for the U.S. as they strive to meet this immense growth in demand,” said José W. Fernández, U.S. Undersecretary for Economic Growth, Energy, and the Environment, after the signing. The cooperative effort strengthens international investment in strategic resources essential to not only product manufacturing, but green technology as well. “Almost every electric car and smartphone use these minerals, and in Peru, the vast majority of these crucial metals are yet to be mined,” Silva-Santisteban added. “This is a boon for our planet’s future and the Peruvian economy.” According to the Ministry of Energy and Mines, Peru is the world’s second-largest exporter of copper, ranks third for silver, and holds massive reserves of gold, zinc, and lead. Peru holds more than six tons of lithium reserves and the production of eight crucial ‘green minerals,’ minerals that are needed to support the transition to clean energy technologies, such as iron, lead, molybdenum, indium and graphite. “With the MOU and our participation in MINEXPO, bringing together knowledgeable exporters of services, minerals and machinery, the synergies will create an opportunity that will strengthen foreign investment in strategic resources for green technology, which will lead to even greater international developments,” said Silva-Santisteban. Peru, holding the second-largest ore reserves for both silver and copper in the world, also accounts for substantial global reserves of gold (5.6%), zinc (8%), lead (6.2%), and other metals. Peru has 31 copper projects across 14 regions, representing a potential investment of nearly $39.8 billion. Minister of Energy and Mines, Rómulo Mucho Mamani, highlighted that Peru holds 11% of the world's copper reserves and that these projects could yield an additional two million tons of copper. ### For more information please visit: www.PROMPERU.gob.pe Contact Details The Hoyt Organization Kelly Reynolds +1 310-343-3197 kreynolds@hoytorg.com

October 08, 2024 09:00 AM Pacific Daylight Time

Image
Article thumbnail News Release

Kevel partners with the World’s Largest Home Improvement Retailer to in-house its retail media technology for Orange Apron Media

Kevel

Both Kevel and Orange Apron Media share a common goal: advertising partner success. They understand that having a tangible impact on their partners’ businesses and success transcends traditional revenue goals and emphasizes a symbiotic relationship where growth is intrinsically tied to the prosperity of their clients. While the partnership between Kevel and Orange Apron Media has just officially launched, it promises to continue to bring innovation to the retail media landscape. Kevel, the API-first ad serving company, is formally announcing its partnership with The Home Depot to support its in-house transformation of its retail media network’s, Orange Apron Media Technology. After six years of providing home improvement retail media solutions, Orange Apron Media embarked on a new journey of transformation and innovation. The Orange Apron Media team will rely on Kevel's Retail Media Cloud™ to power its in-house journey as the company continues to transform and innovate its services. As the home improvement retailer looked to lean further into their competitive edge as a specialty retailer, continuing to innovate their retail media offerings and capabilities for advertisers, they knew flexibility and innovation would be vital. Orange Apron Media turned to Kevel’s flexible, API-based Retail Media Cloud TM solution to power its in-house retail media technology. With the addition of Kevel’s Retail Media Cloud TM, Orange Apron Media built a differentiated retail media network and added value to its ad products by enabling advertisers to connect with customers closer to the point of purchase. Working closely with the Kevel team to upgrade its in-house retail media technology, the Orange Apron Media team will continue to double down on its goal to provide advertisers with value and performance. Through this collaboration Orange Apron Media and Kevel will continue to seamlessly integrate retail media offerings into its digital strategies, emphasizing enhancements to the customer experience across both owned and off-site channels through storytelling and personalization leveraging unique first-party data. “Providing the best possible service and experience for our customers and our advertising partners is at the top of our list of priorities,” said Melanie Babcock, vice president of Orange Apron Media and Monetization. “Finding like-minded partners, like Kevel, makes it easier to build custom solutions that help brands connect with customers at the right place and at the right time. When customization is done right, it enhances everyone’s experience.” Both Kevel and Orange Apron Media are dedicated to enhancing their solutions through innovation and continue to stay at the forefront of the constantly evolving digital advertising landscape, making the partnership an excellent fit at a pivotal time in the industry. Kevel continues to stand out amongst ad tech solution providers as the only API-based solution for in-housing retail media technology, allowing retailers to differentiate based on their unique brand and first-party data. Orange Apron Media is forging the path for specialty retailers by developing an enhanced omnichannel customer experience through ads that tell a story across the customer journey, ensuring their advertisers receive at least two-times return on their ad spend. “There has been a large shift in the retail media landscape as brands focus on the retail media networks that deliver real value versus those that are commoditized and not fit for purpose. This is pushing retailers to move from off the shelf solutions to build high-end, differentiated retail media networks,” says James Avery, Founder & CEO Kevel. “Kevel’s flexible API-based Retail Media Cloud was designed specifically to enable retailers like Orange Apron to build customized in-house retail media solutions in a way that really differentiates them, leveraging their unique attributes to provide advertisers with innovative, cutting edge decisioning, ad formats, targeting, and site performance, all while keeping their data safe and secure at scale.” About Kevel Kevel is powering innovative, flexible ad tech infrastructure APIs that fuel its Retail Media Cloud™. This unique offering is the only API-based solution for in-housing retail media technology that enables multi-brand retailers to differentiate based on their unique brand, improving shopper experience while maintaining total control of their first-party data.Kevel believes that every digital retailer should have the capability to build and scale their own distinct ad platform, just like big tech players like Amazon. Customers like Edmunds, Delivery Hero, Sonae, Leroy Merlin, Slickdeals, and other leading retailers and marketplaces all launched their own retail media networks with Kevel.The company has garnered numerous accolades, most recently earning recognition as one of the leading 100 innovative tech start-ups driving the future of brand-to-consumer in 2023 and awarded the MarTech Breakthrough Award for best overall ad tech company in 2022. Learn more at www.kevel.com About Orange Apron Media The Home Depot Retail Media network offers businesses like yours the opportunity to connect with consumers like never before. Regardless of your budget, we have a solution to meet your marketing needs. Choose one of our advertising offerings or mix and match to find what is right for your company and your specific products. The Home Depot advertising department leverages a myriad of online and offline channels to spread awareness of your brand and promote your products. From email advertising to social media branded marketing, these solutions are designed to propel your business and help increase sales. The Home Depot's advertising center tracks customer interest via our website, enabling us to promote your brand through retargeted ads and other off-site channels to keep your products top of mind. Retail advertising is key to setting yourself apart from competitors in an ever-changing market. About The Home Depot The Home Depot is the world's largest home improvement specialty retailer. At the end of the first quarter, the company operated a total of 2,324 retail stores in all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. The company employs approximately 475,000 associates. The Home Depot's stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor's 500 index. The Home Depot is #17 on the 2022 Fortune 500. Contact Details Kevel Jennifer Choo, Director of Marketing +1 973-343-8819 jchoo@kevel.com

October 08, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

NAVEX Unveils Curated AI Content Library to Simplify Compliance and Risk Mitigation

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, introduces its new AI-focused content library designed to help organizations address the rapidly evolving landscape of Artificial Intelligence (AI) regulations and frameworks. As AI technologies become part of daily operations, many organizations find themselves entering uncharted waters regarding effective AI governance. According to Forrester’s September 2023 Artificial Intelligence Pulse Survey, 56% of AI decision-makers said their organization will use generative AI (genAI) in the next 12 months for internal or customer-facing production applications for employee productivity. The stakes are rising, and navigating these challenges without a clear framework can feel overwhelming, leaving companies vulnerable to risks. NAVEX plays a critical role by enabling companies to implement strong controls, automate workflows, and perform comprehensive testing. This approach simplifies complex challenges and transforms them into strategic opportunities. NAVEX’s content library is continuously curated to cover international and industry-specific AI regulations, including emerging standards and compliance requirements. By leveraging this resource, customers can ensure their AI initiatives align with ethical guidelines and regulatory mandates. A.G. Lambert, Chief Product Officer at NAVEX, captures the pivotal moment many organizations face: "As AI technologies revolutionize industries, companies find themselves standing at a crossroads, navigating the intricate landscape of effective AI governance. Our AI content not only empowers risk management professionals to establish crucial controls but also enhances efficiency by automating compliance processes. This dual approach enables organizations to embrace AI technology with confidence, transforming challenges into opportunities for growth and innovation." Key features of the NAVEX AI content library include: Centralized AI Regulatory Resources: Access a consolidated library of global AI regulations and industry-specific guidelines. Streamlined Control Development: Simplify the process of creating and implementing AI-specific controls to align with emerging regulations. Automated Compliance Monitoring: Leverage automation to track compliance requirements and ensure adherence through continuous control testing. Enhanced Risk Mitigation: Identify and mitigate AI-related risks proactively using structured regulatory frameworks. Future-Proof Compliance Strategy: Stay ahead of evolving AI laws and standards, ensuring the organization remains compliant and competitive. NAVEX is enhancing AI governance with its NAVEX One platform that streamlines the process of developing and distributing AI-related policies, ensuring companies stay aligned with fast-changing compliance requirements in the AI landscape. Should employees or third parties have AI-related issues or concerns, the NAVEX One platform offers employees a secure solution to report them. This proactive approach helps organizations identify and mitigate potential risks early on. The NAVEX content library offers over 400 regulations and compliance frameworks, continuously expanding to meet the demands of an evolving regulatory environment. This extensive resource includes critical AI regulations such as the EU AI Act, NIST AI Risk Management Framework, and the Colorado Artificial Intelligence Act. As AI governance becomes increasingly critical, NAVEX integrates AI training, incident management, and policy management into this comprehensive resource, ensuring organizations stay ahead of compliance requirements. With real-time updates, businesses can select tailored content to meet emerging AI regulatory standards, providing the tools to navigate current and future compliance challenges effectively. This seamless integration helps organizations maintain a proactive risk and compliance posture while leveraging cutting-edge technologies. The new AI content library is now available as part of NAVEX’s Integrated Risk Management solution. For more information, visit NAVEX’s Website. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

October 08, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Danmarks Blomstrende Spille- og casino-scene: Nye Innovationer og Ansvarligt spil

AM Europe

København, Danmark - [October, 4th] - Danmarks spil- og gamblingkultur fortsætter med at blomstre, præget af innovative nye spil, spændende begivenheder og et stærkt engagement i ansvarligt spil. Med en rig spilhistorie omfavner danske spillere de nyeste trends, samtidig med at de nyder godt af en robust lovgivningsmæssig beskyttelse, der sikrer et sikkert spilmiljø. Spændende nye spil lanceres dette efterår Denne sæson vil flere spilleselskaber lancere spændende nye titler, der lover at forbedre spiloplevelsen for danske spillere. Fra fordybende online slots til engagerende live dealer-spil kan spillerne se frem til banebrydende grafik og innovativt gameplay. Bemærkelsesværdige udgivelser inkluderer " Viking Quest ", en spændende eventyrautomat, der fejrer Danmarks rige historie, og "Nordic Roulette", der kombinerer klassisk casino-spænding med et tydeligt dansk twist. Store casino-begivenheder i horisonten Casino Copenhagen gør klar til sit årlige "Danish Poker Championship", hvor spillere fra hele landet vil konkurrere om pengepræmier og den eftertragtede mesterskabstitel. Arrangementet finder sted den 15.-17. november og vil tiltrække både erfarne professionelle og entusiastiske amatører. Deltagerne kan forvente en weekend fyldt med dygtighed, strategi og kammeratskab, der afspejler den livlige ånd i Danmarks pokersamfund. Forpligtelse til ansvarligt spil Danmark er stolt af sine stærke lovgivningsmæssige rammer, som sikrer, at spilaktiviteter udføres retfærdigt og ansvarligt. Den danske Spillemyndighed fører tilsyn med alle spiloperationer og håndhæver strenge regler, der beskytter spillerne. Dansk lov kræver, at operatørerne giver klar information om risici ved spil, så spillerne kan træffe informerede valg. Desuden er initiativer, der har til formål at fremme ansvarligt spil, i højsædet i det danske spillelandskab. Spillere opfordres til at sætte grænser for deres forbrug, og mange operatører tilbyder muligheder for selvudelukkelse for at hjælpe dem, der måske har brug for en pause fra spil. What is ROFUS? ROFUS, det danske onlinespilleregister, er et vigtigt initiativ, der er etableret for at fremme ansvarligt spil i hele Danmark. ROFUS administreres af Spillemyndigheden og giver spillere mulighed for frivilligt at udelukke sig selv fra at deltage i onlinespil, siger spil-uden-om-rofus.net. Denne brugervenlige platform giver enkeltpersoner mulighed for at tage kontrol over deres spillevaner ved at sætte personlige grænser eller vælge en midlertidig eller permanent selvudelukkelse. ROFUS blev lanceret for at forbedre spillernes sikkerhed og sikrer, at personer, der kan være i fare for at få spilleproblemer, kan søge hjælp og få adgang til støtte. Ved at stille et centralt register til rådighed fremmer det ikke kun en kultur med ansvarligt spil, men styrker også integriteten i spilindustrien i Danmark. En kultur af fællesskab og sjov Danske spillere nyder godt af en unik blanding af sociale spiloplevelser, både online og på fysiske kasinoer. Kammeratskabet mellem spillerne er et afgørende træk ved den danske spillekultur, hvor deling af strategier og fejring af gevinster skaber et indbydende miljø. I takt med at branchen udvikler sig, er Danmark fortsat forpligtet til at fremme en sikker og fornøjelig spilleatmosfære. Med nye spil, spændende events og ansvarlige regler på plads ser fremtiden for spil og gambling i Danmark lysere ud end nogensinde. Contact Details Oliver Damgaard +45 27 35 72 27 oliver@cspeed.com

October 04, 2024 11:45 PM Eastern Daylight Time

Image
Article thumbnail News Release

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

Article thumbnail News Release

Methode Electronics Inc. Has Been Implicated In A Securities Fraud Class Action Lawsuit – Here's How Investors Can Get More Information

Benzinga

By Meg Flippin, Benzinga Methode Electronics Inc. (NYSE: MEI) is under the spotlight amid a class action lawsuit filed in the United States District Court for the Northern District of Illinois against the company and former executives for allegedly engaging in securities fraud. The action, Marie Salem v. Methode Electronics Inc., et al., impacts investors who purchased or acquired shares of Methode Electronics between June 23, 2022, and Mar. 6, 2024. Methode is a Chicago-based designer and manufacturer of custom-engineered parts used in transportation, cloud computing infrastructure, construction, consumer appliances and medical devices. Most of its revenue is derived from its automotive segment, which had reportedly been humming along until 2020. With car manufacturers using fewer designs featuring buttons and knobs, favoring display screens and infotainment, Methode shifted its focus. Methode opted to move away from its low-mix but high-margin parts business into specialized components targeted at electric vehicle manufacturers instead of traditional car companies, which appeared to promise to bring higher margins and more sales – but that transition proved to be rocky, and the company allegedly hid its woes from investors, leading to the class action lawsuit. Transition To Speciality Components Rocky According to the lawsuit, during the transition period, the company made materially false and/or misleading statements and failed to disclose material adverse facts about operations and its prospects. The lawsuit points specifically to the company misleading investors or failing to disclose to them the operational, logistics and personnel problems that plagued the transition. What’s more, the lawsuit contends Methode did not disclose setbacks at its Monterrey facility during the transition caused by turnover, poor operational decisions, issues with vendors and supply-chain snafus that led to production planning delays, inventory shortages and what the lawsuit calls “botched” execution of the company’s plan. On top of that, the company incurred increased costs and delayed launches as it attempted to retool the plant to produce the specialty components. All told, the lawsuit states the “company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.” The lawsuit explains that this all started showing up in March 2023 when the company’s automotive unit missed sales targets for the third quarter and lowered its full-year 2023 diluted earnings per share guidance, sending the stock down 13% over the course of multiple trading sessions. The bloodletting didn’t stop there, with the company announcing a series of earnings misses in the subsequent quarters which weighed on the stock. Finally, in March 2024 when reporting its third-quarter 2024 results, Methode announced its automotive segment suffered an $11 million loss from operations, prompting it to withdraw its prior guidance citing “operational challenges” at its Monterrey facility. The company told investors its prior guidance should no longer be relied upon. To improve operations, the company announced it was cutting its headcount and discretionary expenses and is unloading non-core assets. On a conference call at the time to discuss results, the company’s new chief executive officer, Avinash Avula, said Methode’s sales for the third quarter were down $21 million year-over-year “entirely [attributable to] our Auto segment.” That drove the stock down about 31%. Here’s How Methode Investors With Losses Can Find Out More Information About Their Rights Kessler Topaz Meltzer & Check, LLP has earned a reputation for prosecuting class actions in state and federal courts throughout the United States and globally. It reports that it has successfully recovered billions of dollars for victims of fraud and other corporate misconduct. The firm is encouraging Methode investors who have suffered significant losses to directly contact it for more information. To potentially qualify as a lead plaintiff in the Methode class action lawsuit, investors must take action no later than October 25, 2024. They can move the court to serve as lead plaintiff either through Kessler Topaz Meltzer & Check, LLP, or other legal counsel. Alternatively, investors can choose to do nothing and remain as absent class members. A lead plaintiff is a representative party who acts on behalf of all class members in the litigation. This individual or small group of investors typically has the largest financial interest and is considered adequate and typical of the proposed class of investors. The lead plaintiff also selects legal counsel to represent both the lead plaintiff and the class. If the court approves these attorneys, they become lead or class counsel. Applying to become a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit. CLICK HERE to submit your Methode losses or contact an attorney to discuss your rights: Jonathan Naji, Esq. (484) 270-1453 or email at info@ktmc.com. Link also available here: https://www.ktmc.com/new-cases/methode-electronics-inc?utm_source=benzinga&utm_medium=article&utm_campaign=mei&mktm=bzb Featured photo by Timothy Dykes on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 27, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Article thumbnail News Release

Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment

Global Markets News

A new report by PESG Research highlights Nuvectis Pharma's (NASDAQ: NVCT) drug candidate NXP900 and its potential role in the treatment of Non-Small Cell Lung Cancer (NSCLC). The review focuses on NXP900's unique approach to addressing critical challenges in cancer therapy resistance. NXP900 is positioned as a potential significant player in NSCLC treatment, comparing its approach to Summit Therapeutics' ivonescimab. NXP900's mechanism of action targets SRC/YES1 kinases in EGFR and ALK resistant NSCLC patients, offering a novel approach to overcoming treatment resistance. Preclinical studies, as noted in the report, indicate that NXP900 could enhance the efficacy of existing therapies like AstraZeneca's osimertinib (Tagrisso) when used in combination. The report also mentions NXP900's potential beyond NSCLC, including possible applications in other cancers such as squamous cell carcinoma. Context: The Current NSCLC Treatment Landscape The report comes at a time of significant developments in NSCLC treatment. Recently, Summit Therapeutics (NASDAQ: SMMT) made headlines with its drug ivonescimab, which showed promising results in a Phase 3 trial conducted in China. In this trial, ivonescimab outperformed Merck's Keytruda (NYSE: MRK), a current standard of care in many NSCLC cases. This breakthrough has intensified interest in novel approaches to NSCLC treatment, particularly those addressing resistance mechanisms. The report highlights the different approaches being developed to tackle NSCLC. While Summit's ivonescimab targets PD-L1 expression, Nuvectis' NXP900 focuses on EGFR and ALK mutations. The report suggests that this diversity in treatment approaches could be important in providing comprehensive options for NSCLC patients. Nuvectis Pharma's NXP900: Current Status and Potential NXP900 is currently in Phase 1 clinical trials, with a focus on safety and pharmacokinetics evaluations. The report emphasizes the preclinical data supporting NXP900, noting its activity against NSCLC models resistant to standard treatments and its potential synergistic effects when combined with existing therapies. A key feature of NXP900, as highlighted in the report, is its ability to inhibit both catalytic and scaffolding functions of SRC and YES1, which are described as key drivers of cancer cell survival. Implications for Cancer Treatment The Report underscores a trend in oncology: the focus on overcoming treatment resistance. It notes that as patients face progression despite initial responses to immunotherapies or targeted treatments, there's a growing need for novel approaches. NXP900's approach to targeting SRC/YES1 kinases seems is positioned as a unique strategy strategy compared to other emerging therapies. This diversification of approaches could be important in providing multiple avenues to tackle the complex mechanisms of treatment resistance. Conclusion The report provides an in-depth look at Nuvectis Pharma's NXP900, positioning it as a noteworthy development in the field of NSCLC treatment. While acknowledging the early stage of NXP900's development, the report highlights its unique mechanism of action and potential to address treatment resistance. The report suggests that as the landscape of NSCLC treatment continues to evolve, NXP900 represents one of several innovative approaches aiming to improve outcomes for cancer patients. As with all early-stage drug candidates, the full potential of NXP900 will only become clear as it progresses through clinical trials and further research. Click here to review the full report: https://finance.yahoo.com/news/pesg-releases-report-nuvectis-pharma-111500319.html * Please make sure to refer to the full dislcaimers and disclosures linked in the report itself when reading it. *** This news alert may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. *** This news alert is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/fcm9n/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news related to innovative companies and industries and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 16, 2024 08:45 AM Eastern Daylight Time

12345 ... 135